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Abstract: Neurodegenerative disorders (i.e., Alzheimer’s disease, Parkinson’s disease, amyotrophic
lateral sclerosis, and spinal cord injury) represent a great problem worldwide and are becoming
prevalent because of the increasing average age of the population. Despite many studies having
focused on their etiopathology, the exact cause of these diseases is still unknown and until now, there
are only symptomatic treatments. Biomaterials have become important not only for the study of
disease pathogenesis, but also for their application in regenerative medicine. The great advantages
provided by biomaterials are their ability to mimic the environment of the extracellular matrix and to
allow the growth of different types of cells. Biomaterials can be used as supporting material for cell
proliferation to be transplanted and as vectors to deliver many active molecules for the treatments
of neurodegenerative disorders. In this review, we aim to report the potentiality of biomaterials
(i.e., hydrogels, nanoparticles, self-assembling peptides, nanofibers and carbon-based nanomaterials)
by analyzing their use in the regeneration of neural and glial cells their role in axon outgrowth.
Although further studies are needed for their use in humans, the promising results obtained by
several groups leads us to suppose that biomaterials represent a potential therapeutic approach for
the treatments of neurodegenerative disorders.
Keywords: biomaterials; neurodegenerative disorders; spinal cord injury; regenerative medicine;
tissue engineering; stem cells
1. Introduction
1.1. Neurodegenerative Disorders
Neurodegenerative disorders (NDs) are a broad class of disorders characterized by the progressive
loss of disease-specific neural population and they include Alzheimer’s disease (AD), Parkinson’s
disease (PD), amyotrophic lateral sclerosis (ALS), and spinal cord injury (SCI). NDs are a growing
cause of mortality worldwide, particularly in the elderly population. There are many NDs such as
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amyloidosis, taupathies, α-synucleinopathies, and TDP-43 proteinopathies, which are heterogeneous
in clinical presentations and underlying physiology, although often presenting with overlapping
features [1]. The majority of NDs can be divided into familial and sporadic form, depending on the
familial history of the disease. Moreover, NDs are often due to misfolding of physiological proteins in
both neural and glial cells [2].
NDs are usually considered as separate clinical entities because they target different brain areas
and have distinct symptoms. However, they share several common features at the genetic, molecular,
or cellular level (e.g., early vascular dysfunction, the aggregation and spread of misfolded proteins,
selective vulnerability of particular neurons, and activation of immune responses) [3]. Sweeney and
colleagues investigated the role of cerebral blood flow and blood–brain barrier (BBB) integrity in
the pathogenesis of several NDs, finding many similarities [4]. Another hallmark of NDs is the
accumulation of misfolded proteins. Although the proteins are often different for each ND, the process
of protein misfolding and aggregation is remarkably similar, leading to cellular dysfunction, loss of
synapses, and finally brain damage. Furthermore, such proteins can usually self-propagate through
seeding, spreading the pathological abnormalities between cells and tissues [5]. Altered cellular
mechanisms are also very similar between NDs, and they include mitochondrial defects, dysfunctions
in autophagic–lysosomal pathways, synaptic toxicity, and more emerging mechanisms such as the
roles of stress granule pathways and liquid-phase transitions [6]. Finally, for each ND, microglial
cells have been reported to be implicated in neurodegeneration, in particular, because the microglial
responses can shift from neuroprotective to a deleterious role [7].
1.1.1. Alzheimer’s Disease
AD is the most common ND and the first cause of dementia. There are nowadays about 46.8 million
people suffering from AD worldwide. Moreover, the number of AD patients is expected to double
nearly every 20 years [8,9]. In most patients, the causes of AD are idiopathic. It has been proven that
genetics is responsible for familial forms of this disorder, which constitute 1% of all cases. Early onset
AD has been linked to mutations in four genes: the genes encoding amyloid precursor protein (APP),
presenilin 1, presenilin 2, and tau protein [10].
The classical symptoms of AD include dementia, memory and spatial awareness impairment,
movement dysfunction, depression, delusion, and hallucination. Patients also experience anomic
aphasia, acalculia, and apathy [10,11].
Many phenomena leading to AD remain unclear, although there has been significant progress in
the research explaining AD-related changes. The most widely accepted hypothesis is the so-called
amyloid cascade. It consists in the accumulation of amyloid beta (Aβ) due to genetic defects (i.e., APP,
presenilin 1, presenilin 2), environmental factors, and other stressors. These senile plaques induce
an immune response, leading to inflammation, tau hyperphosphorylation, and its aggregation in
tangles [12] that lead to neuron degeneration and death, and impairing neurotransmission in many
brain regions [13].
There are two main symptomatic treatments for AD: acetylcholinesterase inhibitors (i.e., donepezil,
galantamine, and rivastigmine) that increase the availability of acetylcholine at synapses, and the
noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine, which modulates the
opening of the calcium channel [14].
1.1.2. Parkinson’s Disease
PD is the most common movement disorder and the second most common ND. The incidence of
PD is eight to 18 per 100,000 person-years overall, and prevalence reaches 1% in subjects over 60 years
and 3% over 80 years with a higher incidence in men than in women [15]. As in other NDs, there are
two forms: the sporadic form, which represents 90% of the cases, with an early onset, and the familial
form, which represents 10–15% of the cases with an onset beyond 50 years [16,17].
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PD is characterized by the degeneration of dopaminergic neurons of the substantia nigra pars
compacta, which projects to the basal ganglia and to the striatum [18]. It causes motor symptoms such
as the classical triad: tremor, bradykinesia, and rigidity.
In PD, α-synuclein, a protein present in dopaminergic terminals important for synaptic vesicles
trafficking, misfolds, forming oligomers that aggregate in the so-called Lewy bodies [19]. There are
many theories about PD causes and, although different, all of them involveα-synuclein aggregation [20].
Some theories suggest that PD is caused by mitochondrial dysfunction [21], oxidative stress, high levels
of dopamine, and microglia impairment [22,23]. Like a vicious circle, all these theories can explain
α-synuclein aggregation and α-synuclein aggregation can cause all these effects.
The only therapies available for PD are symptomatic ones and the most common are the treatments
with L-DOPA or with dopamine agonists.
1.1.3. Amyotrophic Lateral Sclerosis
ALS, also called “Lou Gehrig’s disease,” is a common ND with an incidence of 2–3 per
100,000 individuals in Europe and 0.7–0.8 per 100,000 individuals in Asia, with a survival of 2–5 years
after onset, which occurs around 65 years of age [24].
It affects both upper and lower motor neurons in the cortex, brainstem, and spinal cord, and it is
associated with weakness, muscle atrophy, and spasticity [24,25].
Although 90–95% of the cases are sporadic, the familial form may represent 5–10% of the total
number of patients, with many genes involved. The most common mutations in both familial
and sporadic cases involve SOD1, TDP-43, FUS, and C9orf72, with the expansion of the GGGGCC
hexanucleotide. However, in recent years, thanks to massive parallel sequencing (whole-genome
sequencing and whole-exome sequencing), progress has been made in the identification of new genes
involved in rare variants [26]. Although the causes of ALS differ, a common histopathological sign
is the presence of intracytoplasmic inclusions such as Bunina bodies, but also SOD1, ubiquitylated,
and TDP-43 inclusions [27].
To this day there are only two drugs approved, the glutamate antagonist Riluzole and the
antioxidant Edaravone, but they have a mild effect.
1.2. Spinal Cord Injury
SCI is a devastating neurological condition that leads to loss of sensory and motor functions. It can
also lead to other significant problems such as bladder and bowel dysfunction, infections, chronic pain,
and cardiac and respiratory issues [28]. SCI impacts on the lives of many people worldwide, with an
estimated number of 27 million people living with this condition [29].
SCI occurs as a result of a traumatic event (i.e., motor vehicle accident, fall, sporting injury or
an act of violence). The trauma is followed by a multifactorial process that involves a complex series
of molecular and cellular events composed of two different phases. The first step is represented by
local cellular damage caused specifically by the traumatic injury and is followed by many secondary
reactive processes including ischemia, inflammation, edema, cell death, axonal degeneration, gliosis,
and formation of scar tissue [30–32].
Treatments currently available for SCI are limited and mainly focus on adaptive and rehabilitative
therapies as well as the management of secondary complications [30,33].
1.3. Current Treatments
Although many studies have focused on the causes of NDs and on possible therapies, the treatments
currently available are limited and they only address symptoms and not the mechanisms underlying
the pathology.
Many problems arise in the treatment of these pathologies. One main problem is the permeability
of the BBB, which prevents administered drugs from reaching therapeutic levels in the brain. For this
reason, there is the need to develop bioactive compounds able to cross the BBB [34]. Other hurdles
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in the treatment of these diseases include the need for such treatments to be safe for a long period.
Finally, there is the need to identify the persons affected by NDs in early stages, as many of them do
not present symptoms at the beginning of the illness [35,36].
A promising strategy to improve intracerebral drug delivery is represented by gene therapy,
which, by altering or inducing the expression of specific genes using modified viral vectors derived
especially from adeno-associated viruses (AAV), can have a great role in neuroprotection, restoration,
and correction of the underlying pathogenic mechanisms. For example, SOD1 is known to play an
important role in the progression of ALS [37] and an injection of AAV carrying a SOD1 silencing RNA
in mice expressing a mutant SOD1 produces long-term suppression of MNs disease [38]. Moreover,
the development of a convection-enhanced delivery (CED) in the 1990s and of a real-time magnetic
resonance imaging (MRI)-guided CED in recent years, has allowed for monitoring of the infusion of
the drug via co-administration of an MRI-contrast agent to have a specified therapy in the anatomical
regions of interest [34]. Many clinical trials, especially for PD [39–41] and AD [42], have begun using
this technique.
In recent years, many studies have focused on protein misfolding. They aim to inhibit the
production of the protein involved in the disease, inhibit the aggregation of such proteins, remove
and prevent their spreading, and to ease their toxic effect. For these purposes, chemical agents were
developed that were able to inhibit aberrant protein aggregation, chemical modulators of autophagy,
and specific antibodies in order to eliminate any misfolded proteins [27,43]. Furthermore, many studies
have focused on the modulation of chaperone proteins and proteasomal components [27].
Another therapeutic angle that has emerged in the past few years is the use of stem cells as a
new approach in the treatment of these pathologies. Stem cells have the ability to renew themselves
continuously and to differentiate into almost all cell types. Different stem cell lines have been explored
in recent years [44]. Mesenchymal stem cells (MSCs) appear to be the most suitable because of their high
availability, satisfactory amounts, and very low immunogenicity. Moreover, they can also differentiate
into neurons and glial cells when cultured under specific conditions [45]. MSCs can be obtained from
several tissues, but the most studied MSCs are those from the umbilical cord (UC-MSCs), bone marrow
(BMSCs), and adipose tissue (ASCs) [46].
Despite having been tested in many studies and clinical trials for different NDs [47], MSCs have
many limitations that need to be overcome for their clinical therapeutic use. Indeed, the complexity of
the neural tissue precludes the potential of many therapeutic approaches based on stem cells. The most
important factor is the lack of correlation between the in vitro and in vivo behavior of stem cells, as the
microenvironment is essential for their differentiation [48]. For this reason, an important challenge
to overcome for the therapeutic use of stem cells in vivo is represented by the understanding of the
surrounding chemical and physical signals as well as cell–cell interactions [49]. Such features can be
easily studied by introducing biomaterials in both in vitro and in vivo models. Biomaterial scaffolds
hold great promise for the generation of innovative 3D culture systems and for in vivo applications
aimed at improving the effect of stem cells in the treatment of brain injuries [50]. Indeed, the ability of
bioengineered scaffolds to mimic the environment of the extracellular matrix (ECM) allows for better
cellular infiltration, resulting in improved proliferation and correct differentiation. Finally, the ability
to control cellular behavior through functionalization suggests that these scaffolds are ideal to be
combined with cells in the field of neural regeneration [50].
2. Biomaterials
2.1. Characteristics of Biomaterials
The science and engineering of biomaterials is a new emerging field. In the past, biomaterials were
defined as “non-vital materials used in medical devices, intended to interact with biological systems”
and they were considered only in the field of medical devices [51,52]. Nowadays, the definition is
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more general, and a biomaterial is considered as “any material, except to drugs, that interacts with
living tissues and performs a particular function without causing adverse effects” [52,53].
Biomaterial evaluation is based on their safety and performance. The biomaterial should
be biocompatible, biofunctional, bioinert, biodegradable, and sterilizable to avoid irritation and
rejection [52,54,55]. The biomaterial, its degradation products, and its sterilization residuals, should
not cause adverse effects in the host tissue (biocompatibility). For this purpose, there are many tests
that can be used to evaluate the toxicity, pyrogenicity, inflammation potential, effects after implantation,
hemocompatibility, and sensitization potential [52,55,56]. Every biomaterial should also be tested for
the clinical effectiveness, that is, if it can produce the desired effects (biofunctionality). A bioinert
material is a material that has no chemical reaction with the tissue. Finally, a biodegradable material is
a material that solubilizes, degrades, or is adsorbed after a certain period of contact with the tissue.
Moreover, the choice of the correct biomaterial is based on physical (wettability, filler, roughness,
softness, and chemical composition), chemical (corrosion properties and surface functional groups),
mechanical (ductility, tensile strength, yield strength, compression strength and fatigue), and biological
properties [55].
Biomaterials are important tools not only in the field of medical devices and regeneration, but
also for the study of different types of cells, involved in different pathologies, in a more physiological
environment. Many are the biomaterials studied and developed in the last years, but the ones that have
shown the best characteristics are hydrogels, nanofibers, carbon-based nanomaterials, and cell-free
scaffolds [50] as reported in the Table S1 (supplementary material).
2.2. Hydrogels
Hydrogels are three-dimensional, highly hydrated, water-insoluble polymer networks held
together by chemical and/or physical crosslinks. They are called physical gels if the molecular
entanglements or secondary forces are the most important actors in the formation of the network; these
types of gels are reversible when changing conditions such as temperature or pH. In chemical gels,
the network is obtained by cross-linking the polymers; these second types of gels can be charged or
uncharged. There are two methods to prepare chemical hydrogels, and these are the three-dimensional
polymerization in which a hydrophilic monomer is polymerized by a cross-linking agent and then
purified, and the direct cross-linking of water-soluble polymers, which do not need purification
procedures [57,58]. The high content of water, the porosity, and the soft consistency of the hydrogels
allow them to transport oxygen, nutrients, and soluble factors to simulate living tissues better than
other biomaterials.
Many types of hydrogels have been studied and used, alone or in a mixture at different ratios in
the field of neurodegeneration and regeneration. These are natural hydrogels like hyaluronic acid (HA),
xyloglucan, collagen, alginate sodium, and gelatin, but also synthetic ones such as polyacrylamide and
polyethylene glycol.
Hydrogels may be used for drug and cell delivery in the study and treatment of NDs. Different
types of cells can be encapsulated in 3D-hydrogel structures, which will then be implanted in the brain
tissue, or the hydrogel itself can be implanted in a pregel state, which will then form a gel directly
in the brain, allowing a more precise localization of the implanted cells. The 3D structures allow the
growth of cells in a permissive environment in which there are both the entry of oxygen and nutrients
and the output of waste products. Moreover, the 3D structure can act as a barrier for the inflammatory
cells or adverse factors in the host tissue [59].
AD. In AD, the studies focused mainly on drug delivery. Peptide-amphiphile hydrogels have
been studied for the release of the antioxidant and neuroprotective compound curcumin [60] and
hydrogels made of gellan gum and xanthan gum for the release of Resveratrol [61]. The encapsulation
of VEGF-secreting fibroblasts into alginate reduced amyloid-β deposition in APP/PS1 mouse models.
Moreover, many studies have shown that the encapsulation of neural stem cells (NSCs) in different
types of hydrogels improved stem cell survival and the cognitive capacities in mouse models [62,63].
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PD. With regard to PD, many authors have focused on dopamine delivery. Senthilkumar and
co-authors in 2007 and, more recently, Ren et al. In 2017, studied the effect of dopamine delivery from
dextran/gelatin and chitosan/ gelatin hydrogels, respectively. Both types of hydrogel showed good
release of the drug and Senthilkumar et al. noticed a behavioral and motor improvement in PD mice
after the treatment [64,65]. Moreover, several neurotrophic factors such as BDNF and GDNF and
epidermal growth factor have been delivered and also combined with embryonic stem cell-derived
dopaminergic neurons in different types of hydrogels. In 2019, Ucar and Humpel encapsulated GDNF
in collagen-hydrogels and noticed an enhancement of dopaminergic cell survival [66], whereas in
2016, Wang and colleagues had already noticed that GDNF released by a poly-L-lactic acid/xyloglucan
hydrogel supported nerve fiber outgrowth and reinnervation of the striatum in a mouse model of
PD [67]. Even more interesting is the possibility of implanting constructs that mimic a neural pathway.
In 2018, Struzyna and colleagues encapsulated embryonic stem cell-derived dopaminergic neurons in
hydrogel micro-columns to reconstruct axonal tracts of the nigrostriatal pathway [68].
ALS. In contrast, few authors have worked on the use of hydrogel in ALS. Osaki and colleagues
developed a 3D human motor unit model in a collagen/Matrigel microfluidic device. They co-cultured
MN spheroids and 3D muscle fiber bundles to mimic the pathological conditions of motor units of
patients with ALS [69]. In 2019, Fantini and colleagues studied the effect of a hydrogel composed of 6%
sodium alginate and 4% gelatin on the viability of different types of cells including induced pluripotent
stem cells (iPSCs) and NSCs. Viability was maintained and the hydrogel printed in a 3D structure
allowed for the 3D organization of the cells, mimicking the environment of the tissue. These results
open the possibility of a new model for the study of ALS, especially in the neuromuscular plaque [70].
SCI. With regard to SCI, hydrogels can be used as scaffolds to fill the lesion cavity and re-connect
the two nerve ends. Stem cells and other biomolecules can be encapsulated in hydrogels, allowing
regeneration and plasticity. Studies have shown that when neural stem cell progenitors (NSPCs)
mixed in platelet-derived growth factor-A encapsulated in a hyaluronan-methylcellulose gel were
transplanted into a rat SCI model, their differentiation and the differentiation of oligodendrocytes
was enhanced [71]. Fibrin-based hydrogels have been utilized to deliver stem cells and growth
factors in SCI rat models. It was demonstrated that embryonic neural stem/progenitor cells (ENSPCs)
encapsulated in this type of hydrogel with different growth factors increased in number, which also
happens for ESNPC derived NeuN+ mature neurons [72]. Pertici and colleagues demonstrated that
poly(N-[2-hydroxypropyl]-methacrylamide) hydrogel implantation into a rat model of SCI induced
locomotor and neurophysiological improvements. This is probably because the hydrogel provides
a more suitable environment for regenerating axons and prevents secondary injury and glial scar
formation, resulting in higher neuroplasticity [73]. A 3D-bioprinted hydrogel scaffold tailored to
the dimensions of the rodent spinal cord was demonstrated to regenerate axons, restoring synaptic
transmission and improving functional outcomes [74]. A recent study also demonstrated that hydrogels
could eliminate the cystic cavities that form after SCI and which represent the major obstacle for tissue
repair. An imidazole-poly(organophosphazenes) (I-5) hydrogel can, in fact, interact with the ECM and
with macrophages of the host tissue, and inhibit the formation of these cavities [75].
2.3. Nanoparticles
As already mentioned, the BBB interferes with the passage of drugs to the brain. Larger systemic
doses of drugs are required to achieve the therapeutic levels in the brain, with adverse effects in the
body. For this reason, there is a necessity for strategies that are able to enhance their concentration in
the brain [34].
Nanotechnology, which consists of the use of materials or devices on a nanometric scale
(1–100 nm), has emerged in the last years as a promising approach to treat different pathologies, like
neurodegenerative disorders. There are different types of nanotechnology devices such as nanoparticles,
nanofibers, nanotubes, nanospheres, and nanogels [76].
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Nanoparticles (NPs) are one of the most preferred nanostructures because of their characteristics:
small size, vast surface, and surface–volume ratios. They can be composed of different materials such
as ceramics, metals, oxides, salts, and polymers. Silica NPs, especially the mesoporous silica NPs with
a pore size of 2–50 nm, are the most frequently used due their large surface area and pore volume;
furthermore, it is easy to control their size and they have a good biocompatibility.
Even so, there are many other types of NPs used in drug delivery: polymer NPs, which are easier
to synthesize and less expensive, gold NPs, protein NPs, and liposomes, which are lipid NPs [76].
AD. The NPs used in NDs began years ago. With regard to AD, many authors have focused
on the delivery of common and available drugs through NPs. Acetylcholinesterase inhibitors
(e.g., Rivastigmine, and anti-amyloid and anti-transferrin receptors) have been loaded in different
types of NPs, demonstrating an increased delivery in rat brains and positive therapeutic outcomes in
amnesic mice [77,78]. The same happens when loading curcumin in this type of NP [79]. NPs have
also been used in metal chelation therapy, which uses metal-chelating compounds to reduce cellular
oxidative stress in AD. It was demonstrated that the use of NPs loaded with chelating compounds
improved drug delivery with benefits both in vitro and in vivo [80]. Moreover, the encapsulation
of epigallotechin-3-gallate, a natural α-secretase promoter, and antioxidant compounds in lipidic
NPs, enhances its neuronal availability in vivo [81]. More interestingly, lipidic nanoparticles were
studied as vaccine carriers against aggregated Aβ peptides and against pathological conformers of
phosphorylated tau proteins, with successful results [82].
PD. Levodopa is the most frequently used drug in the treatment of PD, although it causes many
adverse effects. It was demonstrated that the loading of Levodopa methyl ester in poly-(lactic-co-glycolic
acid) (PLGA) NPs abolishes adverse effects of Levodopa such as dyskinesia [83]. Moreover, it was
shown that the use of lipidic NPs improved dopamine delivery in the brain [84]. Dopamine agonists
(e.g., Bromocriptine, and NADPH oxidase inhibitors) were also encapsulated in NPs to improve their
delivery in the brain with benefits on PD symptoms [85,86].
ALS. With regard to ALS, the use of nanoparticles recapitulates all the strategies adopted for the
other NDs: lipidic nanoparticles [87], the use of curcumin-loaded NPs [88], the use of gold NPs [89],
and of course, the use of NPs for the delivery of available drugs such as Riluzole [90]. One of the
main characteristics of ALS is the high level of oxidative stress. For this reason, oxidative stress is
a target in the treatment with cerium oxide NPs (CeO2 NPs), which have regenerative antioxidant
properties [91,92]. DeCoteau and colleagues demonstrated that CeO2 NPs enhanced strength and
prolonged the life-span of SOD1G93A mice [93].
SCI. In SCI, the use of NPs has shown many advantages in drug delivery: drug-loaded NPs
can give better pharmacokinetics and biodistribution than the free drugs [94]. Methylprednisolone,
a corticosteroid medication, is already used to treat SCI. Many groups have demonstrated that the
use of this treatment in combination with NPs has a better outcome than with methylprednisolone
alone in vivo, with a reduction of the lesion and locomotor improvements [95,96]. Moreover, the use of
poly-ε-caprolactone-based NPs in combination with minocycline, an anti-inflammatory drug, allows for
the reduction of inflammatory response acting on resident microglia cells [97]. However, in the last few
years, new methods have emerged to reduce inflammation in SCI. Park and colleagues reprogrammed
circulating monocytes and neutrophils through PLGA nanoparticles. The authors noticed that the
treatment caused a downregulated expression of proinflammatory factors and an enhanced expression
of anti-inflammatory and pro-regenerative genes, leading to an increased number of regenerating
axons, increased myelination, and enhanced locomotor function [98]. In SCI, magnetic nanoparticles
were used to track specific cells after implantation [99]. It was observed that the injection of stem cells
with magnetic nanoparticles enhanced transfection efficiency and cell viability [100]. More recently, it
was shown that the use of iron oxide nanoparticles along with electromagnetic fields induced sprouting
from mature neurons and axons, significantly less demyelination and more myelinated fibers in injured
rats [101]. Other factors such as neurotrophins [102,103] and the enzyme chABC [104], which has
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already been seen as a promising treatment for SCI, have been loaded in NPs, showing that they can
induce axon regrowth with a controlled and sustained release at the site of the lesion.
2.4. Self-Assembling Peptides
Self-assembling peptides (SAPs) can be monomers or amino acid sequences that assemble to
form nanostructures like tubes, rods, and sheets, allowing the presentation of the peptides’ chemical
functionality on the surface of these structures. These assemblies have different physicochemical
and biochemical activities depending on the morphology, size, and accessibility of the active surface
area [105]. The self-assembly of peptides can be controlled by pH, ionic strength, temperature,
or enzymatic triggers. Moreover, when multiple assemblies are put together, a supramolecular network
can be established. The advantages of these structures are their biocompatibility and the ease of
synthesis [50,106].
There are different types of self-assembling peptides. The simplest building blocks of these
structures are dipeptides, which can assemble into ordered structures in the nanoscale order.
The surfactant-like peptides are, on the other hand, characterized by an amphiphilic structure,
with a hydrophobic tail and a hydrophilic head. When dissolved in water, these types of peptides
assemble to minimize the contact of the tail with the water. In this way, they can form nanotubes or
nanovesicles and they can acquire a function similar to that of lipid micelles present on the lipid layer
of the cells [105,107,108]. The most common modification of peptides with a hydrophobic tail and a
hydrophilic head is the link with a hydrophobic alkyl chain; when combined with an alkyl chain in a
water solution, the hydrophobic tail forms a 3D structure, similar to what happens during protein
folding. These modified peptides form structures such as micelles, vesicles, nanofibers, and nanotubes.
Moreover, modification of surfactant-like peptides produces bola amphiphilic peptides, which have
two hydrophilic heads instead of one. The heads can be of two different types, forming an asymmetric
bola amphiphilic peptide [105].
The ionic-complementary peptides are characterized by an alternating arrangement of negatively
and positively charged residues, whereas cyclic peptides are composed of amino acids forming a
cylindrical structure. Cyclic peptides allow for more stable structures than the ones composed of
linear peptides.
Self-assembling peptides allow the formation of different nanostructures: nanofibers; nanotubes,
which are similar to nanofibers, but with a hole in the inner side where several drugs can be
loaded; nanoparticles, which range from nanospheres to various solid structures; nanotapes; and
hydrogels [105].
In the last years, self-assembling peptides have been used in many fields (e.g., in drug delivery
and in neuronal regeneration) with regard to NDs.
The Tat (YGRKKRRQRRR) peptide is able to penetrate through the cellular membrane, while its
modified form, the Tat-polyethylene glycol-b-cholesterol (Tat-PEG-b-col) peptide, which is able to form
micelles, was used for drug delivery through BBB.
AD. Yu et al. used Lactoferrin-modified polymersomes to deliver the neuroprotective peptide
humanin in an AD mouse model, showing a better drug delivery due to these types of peptides [109].
More recently, self-assembling β-sheet peptides were being studied as a nanoplatform for vaccination.
These assemblies are stable, resistant to proteolysis, and they can carry many antigenic determinants
to elicit a stronger immune response [110]. To allow the growth and differentiation of stem cells in
biomaterials, it is important to create an environment similar to the ECM. Along with other peptides
that have been studied for the development of an ECM-like biomaterial, amyloids seem to be promising
peptides for the control of stem cell behavior. In fact, their formation from soluble proteins is associated
with numerous degenerative diseases. Jacob and colleagues developed amyloid nanofibrils, composed
of Fmoc-protected peptides derived from β-sheet prone C-terminal Aβ42, to create a hydrogel for
the development of stem cells. This hydrogel allows for the proliferation and attachment of the cells,
and supports the differentiation of MSCs [111]. It was also demonstrated that the β-amyloid peptide
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(Aβ) influences neurogenesis [112,113]. Mehrban and colleagues demonstrated that self-assembling
fibers (SAF) based on α-helical coiled-coil peptides were able to create an environment that allows
not only for the attachment of NSCs, but also their differentiation in neurons [114]. The combination
of stem cells with SAFs could allow the culture of cells in an in vitro environment morphologically
similar to that found in vivo. The possibility of obtaining tissue specific SAFs due to specific peptide
sequences or stiffness, allows for the differentiation of cells into a specific lineage. It is important not
only for cell transplantation in neurodegeneration, but also for a good disease modeling [50].
SCI. The most predominant use of these structures has been in the study of SCI and nerve
regeneration. In 2009, it was demonstrated that self-assembling peptide scaffolds composed of
RAD16 allowed for reconnection of the injured spinal cord and axonal regeneration, improving
locomotor functional recovery in injured rats [115]. RAD16-I and RAD16-II, commercially available
SAPs that assemble due to complimentary charge and hydrophobic interactions, have been proved
to be a good substrate for neurite outgrowth [116]. SKPPGTSS, -PFSSTKT-, and RGD motifs
combined with RAD16-I increased levels of nestin, β-tubulin, and other neuronal markers [117,118].
Zhao and colleagues demonstrated that the combination of the self-assembling peptide QL6 with
neural precursor cells (NPCs) enhanced neuro-behavioral recovery, increased neuronal conduction,
and improved survival [119]. In the same year, it was demonstrated that QL6 enhanced not only
neuronal differentiation and axonal regeneration, but also suppressed astrocytic development with
a reduction in post-traumatic apoptosis, inflammation, and astrogliosis [120]. Both these results
were then confirmed by Zweckberger and colleagues in clip-compression SCI rats [121]. Recently,
the ability of these structures was demonstrated to release important trophic factors. Injured rats were
injected with a BDNF-loaded IKVAV peptide amphiphile hydrogel, resulting in axon preservation and
astrogliosis reduction without any inflammation reaction [122]. It the importance of vascularization in
these types of models has also emerged. It was seen that after the normal inflammation caused by SCI,
the density of vasculature significantly decreased. For these reasons, vasculature transplantation with
a blood-spinal cord barrier (BSCB), which protects from inflammation, can potentially stabilize the
vasculature within the cord. With this purpose, Tran and colleagues used a self-assembling peptide
scaffold RADA16-I containing microvascular cells in injured rats and noticed reduced inflammation
and glial scar formation, with an increase in the density of growing axons [123].
2.5. Nanofibers
As previously reported, for tissue engineering, it is fundamental that scaffolds mimic the native
tissue. In the brain, an axon can be considered as a bundle of ultra-small fibers with supporting cells
wrapped around them. Moreover, collagen fibers and capillaries have a fascicle-like structure, important
not only for neuronal survival and function, but also for contact guidance in signal transmission [124].
To mimic the fibrous structure of the brain tissue, electrospinning is used to produce nanofibers of
various polymeric materials [125,126]. In particular, electrospinning has been intensively applied
because of its simplicity, reproducibility, and diversity in producing fibers with various diameters
and with different topographical features [127]. Another advantage of using electrospun nanofibers
is the large surface-area/volume ratio, making them an optimal bioactive matrix for cell attachment,
molecule loading, and functionalization in order to provide enriched biochemical and biophysical
features to improve tissue regeneration. Finally, nanofibrous scaffolds incorporated with various native
proteins have demonstrated a critical role for topographical cues in the functions of MSCs and their
differentiation into neural cells [125].
Although many studies have been conducted for neurite regeneration and synapses formation,
only a few of them have reported on the treatment of NDs, and all of them were focused on the
differentiation of stem cells into dopaminergic neurons for the future treatment of PD [128,129]. Many
materials can be used to produce nanofibers for neurite regeneration, leading to the obtainment of
several scaffolds with various interesting features. A fundamental characteristic that nanofibers must
have is the correct alignment, making them particularly useful for axon regrowth. Subramanian and
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colleagues tested the effect of both aligned and random nanofibers on Schwann cells and proliferation,
finding an improved effect of aligned nanofibers, probably because they can mimic the fibrin cable
architecture [130]. Another similar study demonstrated the effect of aligned nanofibers in iPSC-derived
NSCs. Lin and colleagues found that poly-L-lactic acid nanofibers were able to promote the adhesion,
growth, survival, and proliferation of NSCs, but more importantly, aligned nanofibers greatly directed
neurite outgrowth from the NSCs and significantly promoted neurite growth along the nanofibrous
alignment [131]. Nanofibers can be composed of synthetic materials, but they can be generated starting
from natural compounds. Yin et al. tested and evaluated the effect of collagen nanofibers on a culture
of NSC-derived neurons in the formation of neural networks. In particular, they investigated the
miniature excitatory postsynaptic currents, finding an increased frequency in the differentiated neurons
cultured on collagen nanofibers with respect to that of the collagen-coated control, suggesting the role
of the topography for the beneficial effect of biomaterials [132]. Nanofibers can be loaded with drugs,
and to this end, Lau and colleagues investigated the effect of chitosan nanofibers loaded with genipin.
They found an increased stiffness, resistance to swelling, and lysozymal degradation of nanofibers,
resulting in a better alignment and proliferation of the Schwann cell culture. Finally, in a model of
peripheral nerve regeneration, neurite growth rate upon genipin-treated nanofibers demonstrated a
100% increase [133].
Nanofibers can be produced using materials with a high biocompatibility, and for this reason, many
studies have been conducted in vivo, often obtaining promising results. A polycaprolactone/carbon
nanofiber sheets composite was first tested in vitro and then in vivo. Farzamfar and colleagues found
that such nanofiber sheets implanted in rat sciatic nerve promoted cell attachment, proliferation,
and neurite out-growth [134]. Another useful functionalization of polycaprolactone has been obtained
with laminin. Chang and colleagues found that the functionalization was essential for the correct
organization of neural cells in a rodent model of nerve injury. Moreover, they found numerous new
blood capillary-like structures around the regenerated nerve, leading the authors to hypothesize that
new blood vessel formation could be one of the key factors for successful nerve regeneration [135].
Nanofibers can be loaded not only with peptides or drugs, but also with a combination between these
two compounds in order to obtain a synergic effect in neural regeneration. Satish and Korrapati loaded
polyvinyl cinnamate nanofibers with laminin-derived cell-adhesion peptides to improve selective
neural adhesion and regeneration. Furthermore, they encapsulated triiodothyronine within the
nanofibers for its sustained release to bolster regeneration and reinstate the lost functionality to the
damaged nerve. They found that such nanofibers were biocompatible, improved the cell adhesion rate,
and illustrated favorable interaction with cells in an adult zebrafish model. They concluded that the
combination of aligned nanofibers providing topographical cues, peptides, and triiodothyronine has
robust potential in restoring functionality of the injured nerve [136]. The possibility to inject nanofibers
can open new possibilities for SCI. Li and colleagues developed an injectable nanofiber–hydrogel
composite and implanted it in an adult rat model of spinal cord contusion. After 28 days, they found
that the treated rats had a higher M2/M1 macrophage ratio, blood vessel density, neuron presence,
and axon density, suggesting the fundamental role of this biomaterial in the treatment of SCI [137].
Another interesting approach for nerve regeneration is to create nerve guidance conduits. The coating
of such conduits with nanofibers allows for improvement in the efficacy of regeneration. Shah and
colleagues created a nerve guidance conduit cross-sectional surface composed of spiral structures and
multi-channels, coupled with inner longitudinally aligned nanofibers and protein. After four weeks
from implantation in a rat model with a sciatic nerve injury, they found a shorter recovery time when
compared to the autograft, leading to suppose that such an approach represents a promising tool for
axonal regrowth [138].
2.6. Carbon-Based Nanomaterials
Neural tissue and neural cells have the unique property to generate and transmit electrical stimuli.
Indeed, voltage channels can be modulated by electrical stimulation, influencing not only the firing of
Int. J. Mol. Sci. 2020, 21, 3243 11 of 21
neurons, but also cell proliferation, migration, and function [139]. For this reason, electrical stimuli are
now considered as one of the most promising tools for non-chemical methods for the regeneration
of neural tissue [140]. One of the major issues is the development of an electroactive biomaterial
with excellent biocompatibility, which should support cell growth and contribute to electrical signal
transfer. Carbon based materials (e.g., graphene and carbon nanotubes (CNTs)) are expected to play a
pivotal role in neural regeneration because of their outstanding physical, chemical, and mechanical
properties [141]. Although many studies have tried to improve the biocompatibility of CNTs, they have
many safety issues, causing potential oxidative stress, free radical production, peroxidative product
accumulation, DNA damage, and inflammation. Such biocompatibility problems are important
obstacles to overcome for the potentially wide applications of CNTs in ND therapy [142]. In contrast,
because of their electrical features, they represent a promising tool for nerve regeneration.
Graphene consists of a layer of carbon atoms arranged in a hexagonal honeycomb lattice;
in particular, graphene-family nanomaterials have been identified as new biomaterials for several
biomedical applications such as nanocarriers, biosensors, and the neural regeneration of excitable
cells [141]. To improve cell-substrate adhesion, graphene needs to be coated with a precoating layer
such as laminin, collagen, Matrigel, and poly-l-lysine. Li and colleagues used graphene coated with
poly-l-lysine in a hippocampal culture model and found that the scaffold induced the upregulation of
growth-associated protein 43, contributing to neurite outgrowth [143]. Cell viability and morphology
were evaluated to exclude possible adverse effects of the graphene. An important factor to be
considered is the surface topography and the mechanical properties of the microenvironment: Solanki
and colleagues intriguingly reported that a grid pattern promoted neural differentiation, while a
square pattern promoted glial differentiation [144]. The topography is important for the guidance
of neurite growth. Lee’s group developed a system aimed at obtaining a very precise line pattern
with a 15 µm width and 8 µm spacing. Such topography was reported not only to enhance the
adhesion and growth of primary hippocampal neurons, but also to influence the direction of neurite
outgrowth [145]. The models previously described were composed of a 2D layer of graphene, but this
material can be used for the generation of 3D scaffolds. One of the main aims of tissue engineering
is to mimic the 3D architectures of tissues and organs, but at the same time, the structure has to
ensure efficient cellular metabolism, oxygen and nutrient transportation, and waste removal [146].
Intriguingly, 3D graphene scaffolds were proven to induce much milder neuroinflammation compared
to 2D films, allowing for a better biocompatibility [147]. Examples of the 3D graphene-based scaffold
are the so-called graphene foams that were demonstrated to support the growth and differentiation of
neural cells [148]. Graphene family nanomaterials are usually used as bioactive supporting material,
but they can be utilized as interfacing materials for neurons in composite scaffolds. A substrate of
graphene-incorporated chitosan showed enhanced adhesion, proliferation, and, more importantly,
neurogenesis of adipose-derived hMSCs [149]. Such effects are due to both its nanotopology and
electrical properties. Neural regeneration of graphene materials was tested in a small number of
in vivo models. Wang and colleagues tested a nanofibrous scaffold combined with graphene in a rat
model with a sciatic nerve injury. They found that nerve regeneration and consequent functionality
were similar to the gold standard autograft [150]. In the study of Qian and colleagues, the effects of
graphene nanoscaffolds in nerve repair were evaluated both in vitro and in vivo, showing excellent
functional and morphological recovery, again equivalent to those of autografts. Interestingly, they
found a pro-angiogenic characteristic of graphene, but to study the potential mechanism behind this
key phenomenon, further studies are needed [151].
CNTs are sheets of graphite rolled into cylindrical tubes with a diameter range of 0.4–2 nm,
and with lengths much longer, ranging from hundreds of nanometers to micrometers [152]. They
can be divided into single-walled CNTs (SWCNTs) and multiwalled CNTs (MWCNTs), depending
on their geometry. As graphene, CNTs can conduct electrical stimuli, making it suitable for neural
tissue engineering. CNTs are particularly used as additives in biomaterials to provide conductive
properties to electrical inert materials. In some works, researchers applied electrical stimuli to the
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scaffold in order to improve the effect of CNTs. Imaninezhad and colleagues found that a scaffold
composed of polyethylene glycol and MWCNTs improved neurite outgrowth and neurite length,
which can be significantly enhanced by electrical stimulation by 2-fold and 1.8-fold [153]. Another
similar work confirmed the hypothesis that electrical stimulation improved not only neurite extension,
but also proliferation, cellular migration, and intracellular connections, which are all critical for
nerve regeneration [154]. CNTs can be used without giving electrical stimulation as they provide
the biomaterial with a differential potential that was found to be effective enough to allow neurite
outgrowth and neural regeneration. Shesthra and colleagues developed a polyurethane-silk scaffold
added with MWCNTs and demonstrated that it significantly enhanced P12 neural differentiation and
maturation with axonal regrowth [155]. SWCNTs can provide enough conductivity properties for
neural differentiation. Bordoni and colleagues found that SH-SH5Y fully differentiates and generates
mature synapses when cultivated on a SWCNTS/cellulose-based scaffold opening for a new approach
in neural regeneration [156]. The possibility of providing conductivity without external stimulation
is fundamental for tissue engineering because it can easily be provided in vitro, while it is hard to
achieve in vivo.
In vivo studies are complicated by the toxicity that can cause CNT-based implantation, although
few groups have evaluated the effect of CNTs in an in vivo situation. CNTs were used for both neural
and nerve regeneration. For neural regeneration, Marei and colleagues engrafted NSCs isolated from
a human olfactory bulb in a rat model. They demonstrated that a co-engraft with CNTs provided
support, enhancing their tendency to differentiate into neurons rather than glial cells [157]. For nerve
regeneration, two studies demonstrated the positive effects of CNTs. In the first, Ahn et al. used a
model of sciatic nerve injury in a rat model and found that in the CNT composite scaffold, the number
of regenerated axons crossing the scaffold, the cross-sectional area of the re-innervated muscles, and the
electrophysiological findings were all significantly improved [158]. In the second, Lee et al. developed
a MWCNT–hydrogel neural scaffold and found that CNTs promoted axon outgrowth [159].
3. Concluding Remarks
Neural disorders remain a clinical challenge in the future and biomaterials represent a promising
tool for their treatment. As previously stated, biomaterials can be composed of either natural
and/or synthetic compounds. The biomaterials used in the studies described above present diverse
characteristics, but all of them were reported to be biocompatible, biofunctional, bioinert, biodegradable,
and sterilizable. Some of them (i.e., hydrogels and NPs) have been particularly used for regeneration
and treatment in the field of NDs because of their specific characteristics. Indeed, hydrogels have
been described as optimal scaffolds for the culture and differentiation of stem cells. Moreover, they
resulted in being an optimal vector for the delivery of specific growth factors to support cell growth
and differentiation. NPs have been reported as promising vectors to deliver many active and protective
molecules for the treatment of NDs. In contrast, SAPs, nanofibers, and carbon-based nanomaterials
have been reported to be useful in the restoration of nerve injury. Indeed, both SAPs and nanofibers
have a fiber-like structure that allows for the correct guidance of axons, promoting and supporting
axon outgrowth. Finally, carbon-based nanomaterials, because of their capacity to boost electrical
conductivity, have particularly been used for axon restoration.
Although biomaterials were tested in both in vitro and in vivo animal models, many studies
have to be conducted before applying such materials for human neural regeneration. Indeed, while
biomaterials have many evident beneficial effects, they can also have some issues regarding safety
in humans, for example, triggering inflammation or an oxidative stress effect. Great advances are
expected to emerge in the near future in the field of biomaterials, allowing for an improvement in the
treatments of human neural disorders.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/9/3243/
s1.
Int. J. Mol. Sci. 2020, 21, 3243 13 of 21
Author Contributions: M.B. and E.S. contributed to the design and the structure of the paper and wrote the
manuscript; F.R. contributed to the literature collection; S.G. contributed to the critical review of the final
manuscript; S.C., O.P., and C.C. contributed to the design and the structure of the paper and guided and critically
reviewed the manuscript drafting. All authors critically read the manuscript and approved the final version to
be published.
Funding: This research was funded by the Italian Ministry of Health (Ricerca Corrente 2019–2020).
Acknowledgments: S.C. would like to acknowledge and thank the Fondazione “Romeo and Enrica Invernizzi”.
F.R. would like to acknowledge and thank the Fondazione Fratelli Confalonieri for financial support during
her PhD.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
ND Neurodegenerative Disease
AD Alzheimer’s Disease
PD Parkinson’s Disease
ALS Amyotrophic Lateral Sclerosis
SCI Spinal Cord Injury
TDP-43 TAR DNA-binding protein 43
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ENSPC Embryonic Neural Stem/Progenitor Cell
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SAP Self-Assembling Peptide
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